Literature DB >> 18777594

Enhanced therapeutic effects for human pancreatic cancer by application K-ras and IGF-IR antisense oligodeoxynucleotides.

Yong-Mei Shen1, Xiao-Chun Yang, Chen Yang, Jun-Kang Shen.   

Abstract

AIM: To investigate the combined effects of K-ras antisense oligodeoxynucleotide (K-ras ASODN) specific to GTT point mutation at codon 12 and type I insulin-like growth factor receptor (IGF-IR) antisense oligodeoxynucleotide (IGF-IR ASODN) on proliferation and apoptosis of human pancreatic cancer Patu8988 cells in vitro and in vivo.
METHODS: K-ras gene point mutation and its style at codon 12 of human pancreatic cancer cell line Patu8988 were detected by using polymerase chain reaction with special sequence primers (PCR-SSP) and sequence analysis. According to the mutation style, K-ras mutation ASODN specific to K-ras point mutation at codon 12 was designed and composed. After K-ras ASODN and IGF-IR ASODN treated on Patu8988 cells respectively or cooperatively, the proliferation and morphological change of Patu8988 cells were analyzed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, colony forming assay and transmission electron microscopy; the expression of K-ras and IGF-IR mRNA and protein in the treated cells was measured by reverse-transcript polymerase chain reaction (RT-PCR) and flow cytometry respectively; apoptosis was determined by flow cytometry. The combined antitumor activity of K-ras ASODN and IGF-IR ASODN was evaluated in BALB/c nude mice bearing human pancreatic cancer inoculated with Patu8988 cells.
RESULTS: The results of PCR-SSP and sequence analysis showed that the human pancreatic cancer cell line Patu8988 had point mutation at codon 12, and the mutation style was GGT-->GTT. 2-32 microg/mL K-ras ASODN and 2-32 microg/mL IGF-IR ASODN could inhibit Patu8988 cells' growth, induce apoptosis and decrease the expression of K-ras and IGF-IR mRNA and protein alone. However, there was much more effective inhibition of growth and induction of apoptosis by their combination than by each one alone. In tumor bearing mice, the combination of K-ras ASODN and IGF-IR ASODN showed a significant inhibitory effect on the growth of transplanted pancreatic cancer, resulting in a statistically significant difference compared with each alone.
CONCLUSION: It has been found that K-ras ASODN combined with IGF-IR ASODN could cooperatively inhibit the growth of Patu8988 cells, and induce their apoptosis via reinforcing specific down regulation of K-ras and IGF-IR mRNA and protein expression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18777594      PMCID: PMC2744007          DOI: 10.3748/wjg.14.5176

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  25 in total

1.  Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy.

Authors:  Jason B Fleming; Guo-Liang Shen; Shane E Holloway; Mishel Davis; Rolf A Brekken
Journal:  Mol Cancer Res       Date:  2005-07       Impact factor: 5.852

2.  K-ras mutation and p16 and preproenkephalin promoter hypermethylation in plasma DNA of pancreatic cancer patients: in relation to cigarette smoking.

Authors:  Li Jiao; Jijiang Zhu; Manal M Hassan; Douglas B Evans; James L Abbruzzese; Donghui Li
Journal:  Pancreas       Date:  2007-01       Impact factor: 3.327

Review 3.  Mutant KRAS in the initiation of pancreatic cancer.

Authors:  Therese Deramaudt; Anil K Rustgi
Journal:  Biochim Biophys Acta       Date:  2005-09-07

4.  Targeting inhibition of K-ras enhances Ad.mda-7-induced growth suppression and apoptosis in mutant K-ras colorectal cancer cells.

Authors:  I V Lebedeva; Z-Z Su; L Emdad; A Kolomeyer; D Sarkar; S Kitada; S Waxman; J C Reed; P B Fisher
Journal:  Oncogene       Date:  2006-08-21       Impact factor: 9.867

5.  Bcl-XL antisense oligonucleotides coupled with antennapedia enhances radiation-induced apoptosis in pancreatic cancer.

Authors:  Toshihiko Masui; Ryo Hosotani; Daisuke Ito; Kazuhiro Kami; Masayuki Koizumi; Tomohiko Mori; Eiji Toyoda; Sanae Nakajima; Yoshiharu Miyamoto; Koji Fujimoto; Ryuichiro Doi
Journal:  Surgery       Date:  2006-08       Impact factor: 3.982

6.  VEGF antisense therapy inhibits tumor growth and improves survival in experimental pancreatic cancer.

Authors:  Hubert G Hotz; O Joe Hines; Rizwan Masood; Birgit Hotz; Thomas Foitzik; Heinz J Buhr; Parkash S Gill; Howard A Reber
Journal:  Surgery       Date:  2005-02       Impact factor: 3.982

7.  Small interfering RNAs targeting mutant K-ras inhibit human pancreatic carcinoma cells growth in vitro and in vivo.

Authors:  Hong Zhu; Zhi Yong Liang; Xin Yu Ren; Tong Hua Liu
Journal:  Cancer Biol Ther       Date:  2006-12-30       Impact factor: 4.742

8.  [The study of the effect of antisense oligonucleotide specific to K-ras point mutation on human pancreatic carcinoma cell PC-2].

Authors:  Yong-xiang Wang; Liang Gao; Zong-zheng Ji
Journal:  Zhonghua Wai Ke Za Zhi       Date:  2005-11-01

9.  Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving?

Authors:  S S Nitecki; M G Sarr; T V Colby; J A van Heerden
Journal:  Ann Surg       Date:  1995-01       Impact factor: 12.969

10.  K-ras mutations in stools and tissue samples from patients with malignant and nonmalignant pancreatic diseases.

Authors:  C Berndt; K Haubold; F Wenger; B Brux; J Müller; P Bendzko; T Hillebrand; E Köttgen; J Zanow
Journal:  Clin Chem       Date:  1998-10       Impact factor: 8.327

View more
  8 in total

Review 1.  Pancreatic cancer: molecular pathogenesis and new therapeutic targets.

Authors:  Han H Wong; Nicholas R Lemoine
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-06-09       Impact factor: 46.802

2.  Insulin-like growth factor-I receptor in proliferation and motility of pancreatic cancer.

Authors:  Minoru Tomizawa; Fuminobu Shinozaki; Takao Sugiyama; Shigenori Yamamoto; Makoto Sueishi; Takanobu Yoshida
Journal:  World J Gastroenterol       Date:  2010-04-21       Impact factor: 5.742

3.  Insulin-like growth factor receptor-1 expression predicts postoperative recurrence in adenocarcinoma of the lung.

Authors:  Makoto Nakagawa; Hidetaka Uramoto; Hidehiko Shimokawa; Takamitsu Onitsuka; Takeshi Hanagiri; Fumihiro Tanaka
Journal:  Exp Ther Med       Date:  2011-04-26       Impact factor: 2.447

4.  Translational Approaches towards Cancer Gene Therapy: Hurdles and Hopes.

Authors:  Jaleh Barar; Yadollah Omidi
Journal:  Bioimpacts       Date:  2012-09-22

Review 5.  Gene therapy in pancreatic cancer.

Authors:  Si-Xue Liu; Zhong-Sheng Xia; Ying-Qiang Zhong
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

6.  Current knowledge on pancreatic cancer.

Authors:  Juan Iovanna; Maria Cecilia Mallmann; Anthony Gonçalves; Olivier Turrini; Jean-Charles Dagorn
Journal:  Front Oncol       Date:  2012-01-31       Impact factor: 6.244

Review 7.  Gene Therapy for Pancreatic Cancer: Specificity, Issues and Hopes.

Authors:  Marie Rouanet; Marine Lebrin; Fabian Gross; Barbara Bournet; Pierre Cordelier; Louis Buscail
Journal:  Int J Mol Sci       Date:  2017-06-08       Impact factor: 5.923

8.  Outlier kinase expression by RNA sequencing as targets for precision therapy.

Authors:  Vishal Kothari; Iris Wei; Sunita Shankar; Shanker Kalyana-Sundaram; Lidong Wang; Linda W Ma; Pankaj Vats; Catherine S Grasso; Dan R Robinson; Yi-Mi Wu; Xuhong Cao; Diane M Simeone; Arul M Chinnaiyan; Chandan Kumar-Sinha
Journal:  Cancer Discov       Date:  2013-02-05       Impact factor: 39.397

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.